Clinical trials: sponsored by Celgene
Ulcerative Colitis
Efficacy and Safety Study of Ozanimod in Ulcerative Colitis
The purpose of this study is to determine whether RPC1063 is effective in the treatment of ulcerative colitis (UC).
- Trial name
- Touchstone (NCT01647516)
- Testing
- Ozanimod
- Where
- 88 sites in United States, Australia and 13 more
- Volunteers
- 199 people
- Sponsor
- Celgene
Carcinoma, Hepatocellular
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
CC-122-HCC-002 is a Phase 1/2 dose escalation and expansion clinical study of CC-122 in combination with nivolumab in subjects with unresectable hepatocellular carcinoma (HCC) who have progressed after or were intolerant to no…
- Trial name
- NCT02859324
- Testing
- CC-122, Nivolumab
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 21 people
- Sponsor
- Celgene
Diffuse B-Cell Lymphoma
Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors
This is Phase 1/2 study of avadomide (CC-122) in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, for first-line treatment of patients with Diffuse B-Cell Large B-Cell…
- Trial name
- NCT03283202
- Testing
- Avadomide (CC-122), Rituximab, Cyclophosphamide 750mg/m2 by IV infusion
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 35 people
- Sponsor
- Celgene
Glioblastoma, Malignant Glioma
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
This study is for newly diagnosed WHO Grade IV malignant glioma patients to determine whether an investigational drug known as marizomib (MRZ) will improve the treatment of newly diagnosed glioblastoma patients by delaying the…
- Trial name
- NCT02903069
- Testing
- MRZ, TMZ, RT
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 66 people
- Sponsor
- Celgene
Multiple Myeloma
Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM
The purpose of this study is to compare the safety and efficacy of Lenalidomide versus Placebo maintenance following melphalan, prednisone and velcade induction therapy in newly diagnosed multiple myeloma.
- Trial name
- ARUMM (NCT02112175)
- Testing
- Lenalidomide
- Where
- 73 sites in Belgium, France and 3 more
- Volunteers
- 46 people
- Sponsor
- Celgene
Healthy Volunteer
A Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ozanimod in Healthy Adult Chinese Subjects
This is a Phase 1, open-label, single-dose study. Approximately 24 Chinese healthy adult subjects will be enrolled to receive a single oral dose of ozanimod 0.46 mg or 0.92 mg (12 subjects per dose cohort).
- Trial name
- NCT04211558
- Testing
- Ozanimod
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Celgene
Solid Tumor, Glioma
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
The purpose of this study is to evaluate the safety, pharmacokinetics, and clinical activity of enasidenib in adults with advanced solid tumors, including glioma, or with angioimmunoblastic T-cell lymphoma (AITL), with an…
- Conditions
- Solid Tumor, Glioma, Angioimmunoblastic T-cell Lymphoma, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT02273739
- Testing
- Enasidenib
- Where
- 12 sites in United States, France
- Volunteers
- 21 people
- Sponsor
- Celgene
Relapsing Multiple Sclerosis
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented within this record. The primary objective of Part B is to assess whether the clinical efficacy of ozanimod (RPC1063) is superior to…
- Trial name
- RADIANCE (NCT02047734)
- Testing
- Ozanimod, Interferon beta-1a
- Where
- 299 sites in United States, Belarus and 19 more
- Volunteers
- 1,320 people
- Sponsor
- Celgene
Relapsing Multiple Sclerosis
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
This study is a two-part trial consisting of Part A (presented in this record) and Part B (see NCT02047734). The primary objective in Part A of this study was to demonstrate the superior efficacy of ozanimod compared to placebo…
- Trial name
- RADIANCE (NCT01628393)
- Testing
- Ozanimod
- Where
- 58 sites in United States, Belgium and 11 more
- Volunteers
- 258 people
- Sponsor
- Celgene
Crohn's Disease
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
The purpose is to determine whether RPC1063 is effective in the treatment of Crohn's disease.
- Trial name
- NCT02531113
- Testing
- RPC1063
- Where
- 28 sites in United States, Canada and 3 more
- Volunteers
- 69 people
- Sponsor
- Celgene
Multiple Sclerosis
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).
- Trial name
- SUNBEAM (NCT02294058)
- Testing
- Ozanimod, Interferon beta-1a
- Where
- 224 sites in United States, Belarus and 23 more
- Volunteers
- 1,346 people
- Sponsor
- Celgene
Solid Tumor
Expanded Access for Marizomib
This is an expanded access program (EAP) for eligible participants designed to provide access to Marizomib.
- Trial name
- NCT04644107
- Testing
- Marizomib
- Where
- United States
- Sponsor
- Celgene
Metastatic Pancreatic Cancer
Treatment of Pancreatic Cancer With Abraxane
This observational program collects data on tolerability, safety and efficacy regarding the use of Abraxane in metastatic pancreatic cancer patients in the daily clinical routine.
- Trial name
- NCT02555813
- Testing
- Abraxane, Gemcitabine
- Where
- 19 sites in Austria
- Volunteers
- 317 people
- Sponsor
- Celgene
Acute Myelogenous Leukemia (AML)
Expanded Access for CC-486
This is an expanded access program (EAP) for eligible participants designed to provide access to CC-486.
- Trial name
- NCT03723135
- Testing
- CC-486
- Where
- United States
- Sponsor
- Celgene
Myelofibrosis
Individual Patient Compassionate Use of Fedratinib
This is an expanded access program (EAP) for eligible participants designed to provide access to fedratinib. Expanded access is only available in markets where fedratinib is not yet approved.
- Trial name
- NCT03723148
- Testing
- Oral Fedratinib
- Where
- United States
- Sponsor
- Celgene
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma
The goal of the study is to identify a dose and schedule of CC-486 that can be safely administered with R-CHOP. To evaluate the safety and maximum tolerated dose (MTD) or the maximal administered dose (MAD) of CC-486 in…
- Trial name
- NCT02343536
- Testing
- Oral Azacitidine, Rituximab, cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 59 people
- Sponsor
- Celgene
Healthy Volunteers
Japanese Pharmacokinetic Bridging Study for CC-93538
This is an open-label, randomized, parallel design study to evaluate the PK, safety, tolerability and immunogenicity of single SC doses of CC-93538 in healthy Japanese and Caucasian adult subjects.
- Trial name
- NCT04096105
- Testing
- CC-93538
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Celgene
Healthy Volunteers
Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites
This is a Phase 1, randomized, parallel-group, open-label study. Forty subjects will be enrolled and will be randomized into 1 of the 2 treatment groups, with 20 subjects in each treatment group(sex will be used as a stratifying…
- Trial name
- NCT04149678
- Testing
- Ozanimod, Cyclosporine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Celgene
Healthy Volunteers
Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects
This is a 2-part study to evaluate the effect of multiple doses of rifampin or efavirenz on the PK, safety, and tolerability of single doses of fedratinib in healthy subjects.
- Trial name
- NCT03983239
- Testing
- Fedratinib, Rifampin, Efavirenz
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Celgene
Squamous Cell Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Maintenance treatment of advanced stage squamous cell NSCLC. Phase III, randomized, open-label, multi-center study of nab-paclitaxel with best supportive care (BSC) or BSC alone as maintenance treatment after response or stable…
- Trial name
- NCT02027428
- Testing
- Abraxane (Induction), Carboplatin (Induction), Abraxane (Maintenance)
- Where
- 119 sites in United States, Germany and 3 more
- Volunteers
- 427 people
- Sponsor
- Celgene